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Ion fluxes mediated by glial cells are required for
several physiological processes such as fluid
homeostasis or the maintenance of low extracellular
potassium during high neuronal activity. In mice, the
disruption of the Cl channel ClC-2 causes fluid
accumulation leading tomyelin vacuolation. A similar
vacuolation phenotype is detected in humans
affected with megalencephalic leukoencephalop-
athy with subcortical cysts (MLC), a leukodystrophy
which is caused bymutations inMLC1 orGLIALCAM.
We here identify GlialCAM as a ClC-2 binding
partner. GlialCAM and ClC-2 colocalize in Bergmann
glia, in astrocyte-astrocyte junctions at astrocytic
endfeet around blood vessels, and in myelinated
fiber tracts. GlialCAM targets ClC-2 to cell junctions,
increases ClC-2 mediated currents, and changes its
functional properties. Disease-causing GLIALCAM
mutations abolish the targeting of the channel to
cell junctions. This work describes the first auxiliary
subunit of ClC-2 and suggests that ClC-2 may play
a role in the pathology of MLC disease.
INTRODUCTION
Megalencephalic leukoencephalopathy with subcortical cysts
(MLC) is a rare type of leukodystrophy (van der Knaap et al.,
1995a) characterized by macrocephaly that appears in the first
years of life. MRI of patients shows swelling of the cerebral
white matter and the presence of subcortical cysts, mainly in
the anterior temporal regions. In MLC patients, diffusionstudies indicate increased water content of the brain (van
der Knaap et al., 1995b). A brain biopsy from an MLC patient
revealed myelin (van der Knaap et al., 1996) and astrocyte
vacuolation (Duarri et al., 2011). It was suggested that MLC
may be caused by impaired ion transport across cellular
membranes, thereby leading to an osmotic imbalance and
disturbed fluid homeostasis (Brignone et al., 2011; Duarri
et al., 2011). Indeed, MLC1, the first disease gene discovered
to underlie MLC in most patients (Leegwater et al., 2001),
encodes an integral membrane protein with 8 putative trans-
membrane domains with low and questionable homology to
ion channels (Teijido et al., 2004). Recently, MLC1 has been
proposed to be related to the activation of the volume-regu-
lated anion channel (Ridder et al., 2011). However, the precise
role of MLC1 in volume-regulated chloride transport is not
clear (Ridder et al., 2011).
Among the ion channels that are expressed in glia, the hyper-
polarization-activated and osmosensitive ClC-2 Cl channel
(Gru¨nder et al., 1992; Thiemann et al., 1992) has been proposed
to be an important player in extracellular ion homeostasis (Blanz
et al., 2007; Fava et al., 2001; Makara et al., 2003). Mice lacking
ClC-2 (Clcn2/ mice) exhibit vacuolation of the white matter
that resembles the pathology of MLC patients (Blanz et al.,
2007). MLC1 mutations account for only 75% of patients with
MLC, but none of the patients without mutations inMLC1 carried
bona fide disease-causing mutations in CLCN2 (Blanz et al.,
2007; Scheper et al., 2010). Tests for a crosstalk between
ClC-2 and MLC1 also gave negative results. The proteins could
not be coprecipitated, and reduction of MLC1 levels by RNA
interference did not change ClC-2 protein levels (Duarri et al.,
2011). Hence, no role of ClC-2 in human MLC could be
established.
GLIALCAMwas recently identified as a secondMLC gene (Lo´-
pez-Herna´ndez et al., 2011a). GlialCAM is an Ig-like cell-adhe-
sion molecule of poorly characterized function (Favre-KontulaNeuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc. 951
Figure 1. Identification of ClC-2 as a Glial-
CAM-Interacting Protein
(A) Scheme of the GlialCAM molecule. Mutated
residues studied in this work are depicted. Anti-
bodies used for purification (mou: mouse; rab:
rabbit) are shown.
(B) Evaluation of GlialCAM affinity purification from
mouse brain. The scheme shows a 2D plot of
relative protein enrichment in affinity purifications
versus IgG controls. Proteins specifically cop-
urified are shown in the yellow area; dashed lines
indicate the specificity thresholds as suggested by
the distribution of all protein ratios (gray circles).
(C), Immunoblot analysis of a sample of the affinity
purification with the anti-GlialCAM rabbit poly-
clonal antibody stained with the same antibody
(upper) and with anti-ClC-2 C1 antibody (lower);
lanes resolve aliquots of pellet after solubilization,
solubilizate (Sol), not bound (NB), or eluates from
the purification (IP Glial). IP IgG: eluate from an IgG
control.
(D) Copurification of GlialCAM with anti-ClC-2 C2
antibody. Lanes were labeled as before.
(E) Coimmunoprecipitation from HeLa cells transiently transfected with ClC-2 and Flag-tagged GlialCAM. Lanes were labeled as before.
(F) Quantification of interaction using the split-TEV assay. ClC-2 was tested for interaction with the proteins indicated below the graph. **p < 0.01;
***p < 0.001 versus 4F2hc.
See also Figure S1.
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A Subunit of ClC-2 Defective in a Leukodystrophyet al., 2008). A role of GlialCAM in MLC was first suggested by
biochemical assays that demonstrated that both proteins bind
each other and colocalize in astrocyte-astrocyte junctions at as-
trocytic endfeet (Lo´pez-Herna´ndez et al., 2011a). GlialCAM
targets MLC1 to cell-cell junctions (Lo´pez-Herna´ndez et al.,
2011b) and GLIALCAM mutations identified in MLC patients
impair the correct trafficking of GlialCAM and MLC1 to astro-
cyte-astrocyte junctions (Lo´pez-Herna´ndez et al., 2011a, 2011b).
Unlike MLC1, GlialCAM is also detected in myelin (Lo´pez-
Herna´ndez et al., 2011a), mainly in oligodendroglial extensions
(Favre-Kontula et al., 2008). In the present work, we show that
GlialCAM interacts with ClC-2 in several glial cell types including
oligodendrocytes, targeting it to cell junctions and dramatically
increasing its conductance. We thus identified GlialCAM as an
auxiliary subunit of ClC-2, potentially implicating the channel in
the pathogenesis of MLC.
RESULTS
Identification of ClC-2 as GlialCAM Binding Partner
We used two different antibodies directed against GlialCAM
(Figure 1A) to identify proteins from solubilized mouse brain
membranes that copurify with GlialCAM. In addition to peptides
from GlialCAM and MLC1, quantitative mass spectroscopy
identified peptides corresponding to the ClC-2 chloride channel
(Figure 1B and see Figure S1 available online) as the only other
consistently and specifically copurified protein in the eluate.
Western blot analysis confirmed that ClC-2 was copurified with
at least a fraction of GlialCAM (Figure 1C), which may result
from a partial dissociation of the complex or may indicate that
not all GlialCAM is associated with ClC-2. Coimmunoprecipita-
tion experiments using an antibody against ClC-2 confirmed
the interaction between GlialCAM and ClC-2 (Figure 1D). Similar952 Neuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc.experiments using extracts from cells transfectedwith ClC-2 and
C terminally tagged GlialCAM (Figure 1E), as well as split-TEV
interaction experiments (Figure 1F), suggested that ClC-2 and
GlialCAM directly interact. The interaction appeared specific
since no association was observed between ClC-2 and the
related 2Cl/H+ antiporter ClC-5, the unrelated polytopic adeno-
sine 2A receptor (A2AR), or the unrelated single transmembrane
span protein 4F2hc (Figure 1F).
Colocalization of ClC-2 and GlialCAM in Tissue
For the interaction of GlialCAM and ClC-2 to be physiologically
relevant, both proteinsmust colocalize in native tissue. GlialCAM
is found exclusively in brain, where it localizes to astrocyte-astro-
cyte junctions at endfeet, Bergmann glia, some pyramidal
neurons and to myelin (Lo´pez-Herna´ndez et al., 2011a). In addi-
tion to neurons, ClC-2 is expressed on astrocytes and oligoden-
drocytes and was found in myelin-enriched fractions (Blanz
et al., 2007; Fava et al., 2001; Fo¨ldy et al., 2010; Makara et al.,
2003; Rinke et al., 2010; Sı´k et al., 2000). GlialCAM colocalized
in mouse brain with ClC-2 in cerebellar Bergmann glia which
was counterstained for GFAP (Figure 2A). Both proteins were
present at astrocytic endfeet surrounding blood vessels (Fig-
ure 2B; Blanz et al., 2007; Lo´pez-Herna´ndez et al., 2011a; Sı´k
et al., 2000) in the cortex and in the cerebellum. In human cere-
bellum, immunogold electron microscopy detected ClC-2 at
astrocyte-astrocyte contacts in the endfeet (Figures 2C and
2D), a location where also GlialCAM and MLC1 are present (Lo´-
pez-Herna´ndez et al., 2011a). GlialCAM and ClC-2 were also
found to colocalize inmyelinated fiber tracts along the circumfer-
ence of oligodendrocytic cell bodies in mouse cerebellum
(Figure 2E), where GlialCAM, ClC-2, and the oligodendrocyte-
expressed gap junction protein Cx47 were present in the same
cell membrane (Figure 2F; Blanz et al., 2007). In vitro cell culture
Figure 2. Localization of ClC-2 and GlialCAM in the Brain
Mouse brain sections labeled with antibodies against GlialCAM, ClC-2, or
GFAP antibodies. (A) cerebellar Bergmann glia; (B) astrocytic endfeet
surrounding blood vessels in cortex; (C and D) EM immunolabeling of human
cerebellum shows localization of ClC-2 (arrows) in astrocyte-astrocyte junc-
tions near basal lamina; (E) oligodendrocytic cell bodies in myelinated fibers of
cerebellar white matter tracts.
(F) Coexpression of GlialCAM and the oligodendrocyte marker Cx47 in
membranes of oligodendrocytic bodies in the cerebellum.
(G) EM immunolabeling detects ClC-2 in myelin (arrows).
Scale bars for (A), (B), and (E) 20 mm; (F) 5 mm; for panels (C) and (D) 200 nm; (G)
500 nm. M: myelin; Ax: axon; Ast: astrocyte; BL: basal lamina. ClC-2 anti-
bodies used: C1 (A); C2 (B–F). See also Figure S2.
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stages of oligodendrocytic differentiation, including the bipoten-
tial O2-A progenitor NG2 positive cells (OPC cells) (Favre-Kon-
tula et al., 2008). Immunogold EM confirmed the presence of
ClC-2 in human myelin (Figure 2G).
Localization and expression of GlialCAM is independent of
MLC1 (Lo´pez-Herna´ndez et al., 2011b). We similarly askedwhether the expression of GlialCAM or MLC1 depends on
ClC-2. Western blots revealed that the total amount of GlialCAM
and MLC1 proteins were unchanged in the brain of Clcn2/
mice (Figure S2A). Likewise, there was no change in the subcel-
lular localization of GlialCAM and MLC1 in Bergmann glia, nor in
the astrocytic endfeet around blood vessels in Clcn2/ mice
(Figures S2B and S2C).
GlialCAM Changes the Subcellular Distribution of ClC-2
We then studied whether GlialCAM changes the abundance or
localization of ClC-2 in heterologous expression systems. We
could not detect that GlialCAM changes ClC-2 protein levels
(data not shown) and ClC-2 surface expression after transfection
of HeLa cells or transduction of primary astrocytes, as ascer-
tained in a chemiluminescence assay (Figure S3).
Since GlialCAM has been described to target MLC1 to
cell-cell junctions (Lo´pez-Herna´ndez et al., 2011b), we as-
sayed if GlialCAM could also modify ClC-2 localization in the
same manner. In HeLa cells, ClC-2 transfected alone was
detected at the plasma membrane and intracellularly (Fig-
ure 3A). Coexpression with GlialCAM directed the ClC-2
channel to cell-cell contacts (Figures 3B–3D), where both
proteins colocalized (data not shown). Localization of ClC-2
together with GlialCAM was observed in long (Figure 3B) or
short (Figure 3C) cell-cell contact processes and in extensive
contact areas between opposite cells (Figure 3D). Such a clus-
tering was never observed in contacting cells expressing only
ClC-2 (Figure 3A). Similar results were observed in HEK293
cells (data not shown). We performed analogous experiments
in primary cultures of astrocytes, where both proteins are
endogenously expressed. In these cultures, adenoviral-medi-
ated expression of ClC-2 with or without GlialCAM showed
that the latter protein was necessary to target ClC-2 to astro-
cyte-astrocyte processes (compare Figures 3E and 3F). In
these junctions, ClC-2 and GlialCAM displayed colocalization
(Figures 3F–3H).
GlialCAM Modifies ClC-2 Currents
We next asked whether GlialCAM could modify ClC-2 function.
Coexpression of GlialCAM and ClC-2 in Xenopus oocytes
dramatically increased ClC-2-mediated currents and changed
their characteristics (Figure 4A). Initial currents measured
at +60 mV were more than 15-fold larger in cells coexpressing
ClC-2 and GlialCAM compared to ClC-2 alone. Whereas ClC-2
currents are strongly inwardly rectifying and activate slowly
upon hyperpolarization, ClC-2/GlialCAM currents were almost
ohmic and displayed time-independent, instantaneously active
currents (Figure 4B). Of note, the apparent inactivation observed
sometimes at very negative voltages is an artifact caused by
chloride depletion inside the oocytes.
Similar effects of GlialCAM on ClC-2 currents were seen in
transfected HEK293 cells, although a residual time-dependent
component was present (Figure 4C). Importantly, GlialCAM
alone does not induce any significant current in HEK cells or
Xenopus oocytes (Figure S4). Similarly, in transfected cells,
ClC-2 steady state currents at +60 mV were dramatically
increased by GlialCAM (Figure 4D). Specificity of the currents
was demonstrated by the characteristic block by extracellularNeuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc. 953
Figure 3. GlialCAM Changes the Subcellular Distribution of ClC-2 in
HeLa Cells and in Primary Cultures of Astrocytes
(A–D) GlialCAM changed the subcellular distribution of ClC-2 in transiently
transfected HeLa cells from being at the plasma membrane when transfected
alone (A) versus being at long cell-cell contact processes (B), at short cell-cell
contact processes (C), or in extensive contact regions (D) when cotransfected
with GlialCAM (arrows label cell-cell contacts). Scale bar: 10 mm.
(E–H) Astrocytes were transduced with adenoviruses expressing ClC-2 alone
or together with C terminally tagged GlialCAM at MOI 3. GlialCAM similarly
brought ClC-2 to cell-cell contacts. Arrows point to astrocyte-astrocyte
contacts. Immunofluorescence used a flag monoclonal antibody detecting
GlialCAM protein (red) or a rabbit polyclonal antibody (C1) detecting ClC-2
(green). Colocalization between the red and the green fluorescence results in
a yellow coloring (Merge). Nuclei of astrocytes were stained using DAPI (blue).
Scale bar: 20 mm.
See also Figure S3.
Neuron
A Subunit of ClC-2 Defective in a Leukodystrophyiodide (Gru¨nder et al., 1992; Thiemann et al., 1992; Figure 4B)
and cadmium (Clark et al., 1998) (data not shown).
To test if GlialCAM may alter native ClC-2 currents we per-
formed whole-cell patch-clamp experiments in differentiated
rat astrocytes. These cells exhibit typical hyperpolarization-acti-
vated ClC-2-like currents that were blocked by iodide (Ferroni
et al., 1997; Makara et al., 2003; Figure 4E). After GlialCAM over-954 Neuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc.expression, currents were increased and showed a large in-
stantaneous component and less rectification (Figure 4F),
qualitatively similar to the effect on ClC-2 in the heterologous
systems. These currents were also blocked by iodide to similar
degree (Figure 4E).
Even if GlialCAM and connexins do not overlap significantly
(Figures 2F and S4D), it may be hypothesized that GlialCAM
expression increases ionic currents by stimulating currents
through gap junction proteins. However, overexpression of
GlialCAM did not modify expression and localization of connexin
43, the major connexin of astrocytes (Figures S4C and S4E).
Furthermore, blocking gap junctions with glycyrrhetinic acid
did not influence GlialCAM-induced currents in coupled astro-
cytes (Figure S4F), which were, however, blocked by iodide
which is known to block ClC-2 (Gru¨nder et al., 1992; Thiemann
et al., 1992; Figure 4F).
We next addressed whether the effect of GlialCAM was
specific to ClC-2. GlialCAM did not change currents of ClC-5
at positive or negative voltages (Figure 5A). We studied if human
GlialCAM could interact with the ClC-2 ortholog from Drosophila
melanogaster (DmClC-2) (Flores et al., 2006), whose genome
lacks a GlialCAM ortholog. GlialCAM interacted biochemically
and increased currents of DmClC-2 (Figures 5B and 5C), sug-
gesting that GlialCAM evolved to interact with the channel at
an interface that is evolutionary conserved among ClC-2 like
channels. Additionally, we addressed interaction with the closest
homolog of GlialCAM named HepaCAM2. No biochemical and
functional interaction was observed between HepaCAM2 and
ClC-2 (Figures 5D and 5E). Finally, we asked whether wild-type
MLC1 or MLC1 containing MLC-causing mutations could influ-
ence ClC-2 or ClC-2/GlialCAM induced current in Xenopus
oocytes. We did not find any effect on ClC-2 mediated currents
(Figure 5F).
Insights into the Molecular Mechanism of ClC-2
Activation by GlialCAM
Currents of Xenopus oocytes expressing GlialCAM/ClC-2
resemble those of an N-terminal deletion of ClC-2 (DN), in which
the osmosensitivity and the voltage-dependence is drastically
altered (Gru¨nder et al., 1992). This might suggest that GlialCAM
activates ClC-2 by interacting with its N terminus. However,
we found that GlialCAM still interacted biochemically with
(Figure S5A) and targeted the DN mutant to cell-cell contacts
(Figure S5B) just like wild-type ClC-2. Moreover, GlialCAM
potentiated DN currents in transfected HEK293 cells
(Figure S5C).
We then compared the functional properties of ClC-2, DN and
GlialCAM/ClC-2. Hypo-osmolarity increased currents of
GlialCAM/ClC-2 and ClC-2, but had no effect on DN (Gru¨nder
et al., 1992; Figure 6A). All of them have the same anion perme-
ability sequence (Figure 6B), strongly suggesting that GlialCAM
has no effect on the open-pore properties of the channel. We
also addressed whether GlialCAM could increase the single
channel conductance of the channel by performing nonsta-
tionary noise analysis of currents induced by ClC-2 or by ClC-2/
GlialCAMat100mV in transfectedHEK cells. The conductance
of ClC-2 was estimated at 2.9 ± 0.4 pS (n = 8), a value very similar
to what has been previously reported (Weinreich and Jentsch,
Figure 4. GlialCAM Modifies ClC-2 Currents in Xenopus Oocytes, HEK Cells, and Primary Rat Astrocytes
(A) Currents mediated by ClC-2 (left) expressed in oocytes and after coexpression of ClC-2 with GlialCAM (right).
(B) Representative steady-state current-voltage relationship of ClC-2 (circles) and ClC-2 coexpressed with GlialCAM (squares) in chloride (open symbols) or
iodide (filled symbols). Average initial currents measured at +60 mV were 0.96 ± 0.17 mA (n = 14) for ClC-2 and 17.2 ± 2.2 mA (n = 10) for ClC-2/GlialCAM.
(C) Typical whole-cell currents from transfected HEK293 cells with ClC-2-GFP alone (left) or together with GlialCAM (right). The GFP tag does not affect ClC-2
current properties.
(D) Average steady-state current voltage from ClC-2-GFP (filled circles) or ClC-2-GFP/GlialCAM (circles) transfected HEK293 cells.
(E) Left: representative trace of whole-cell inwardly rectifying chloride currents in dbcAMP-treated cultured neocortical rat astrocytes. These currents, as
described (Ferroni et al., 1997), were blockedwhen chloride was replaced by iodide (F) andwere not blocked by tamoxifen (data not shown). Right: representative
trace of chloride currents of dbcAMP-treated astrocytes transduced with adenoviruses expressing GlialCAM fused to GFP. The inset shows the voltage
protocol used.
(F) Average steady-state current-voltage relationship of dbcAMP-treated astrocytes (circles, n = 14) or transduced with adenoviruses expressing GlialCAM-GFP
(filled circles, n = 14) in chloride medium. Recordings were performed in symmetrical chloride concentrations. In some recordings chloride was exchanged by
iodide (triangles or filled triangles). At hyperpolarizing voltages iodide block was by 32.7% ± 3.2% for control astrocytes (n = 6) and by 56.8% ± 2.9% for
astrocytes transduced with adenoviruses expressing GlialCAM-GFP (n = 8).
See also Figure S4.
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A Subunit of ClC-2 Defective in a Leukodystrophy2001). For ClC-2/GlialCAM we obtained a value of 2.6 ± 0.2 pS
(n = 8), not statistically significantly different from the value for
ClC-2 alone (p > 0.5). We conclude that GlialCAM does not
modify single-channel properties of ClC-2. Interestingly,
GlialCAM similarly diminished the inhibition by acidic pH of
both ClC-2 and DN (Figure 6C). This result suggested that
GlialCAM may activate ClC-2 by opening the common gatethat acts on both pores of the homodimeric channel, as this
gate is sensitive to acidic pH (Niemeyer et al., 2009).
GlialCAMdisplays a longcytoplasmaticC terminus comprising
about 30% of the protein (Favre-Kontula et al., 2008). However,
consistent with its poor sequence conservation between
species, the deletion of the entire C terminus did not abolish the
interaction with ClC-2, its targeting to cell junctions, and theNeuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc. 955
Figure 5. Specificity of the ClC-2 GlialCAM Inter-
action
(A) Human ClC-5 was expressed in oocytes with and
without GlialCAM. Currents were quantified at positive
(+80 mV) and negative (80 mV) voltages 3 days after
injection. The inset shows representative ClC-5 + Glial-
CAM traces using a voltage-clamp protocol with pulses
ranging from +120 mV to 120 mV in 20 mV steps.
(B) Interaction between DmClC-2 and DmClC-2 or Glial-
CAM was monitored using split-TEV assays. 4F2hc was
used as a negative control. The result is an average of 5
independent experiments. **p < 0.01 versus 4F2hc.
(C) DmClC-2 was expressed in Xenopus oocytes by itself
or together with GlialCAM. Two days after injection in
oocytes DmClC-2 ± GlialCAM currents were determined.
Steady state currents are plotted against voltage (n = 5 ±
SEM). The inset shows representative current traces of
DmClC-2 (filled circle) and DmClC-2 / GlialCAM (open
circle).
(D) Interaction between ClC-2 and GlialCAM or Hep-
aCAM2 by split-TEV assays. 4F2hc was used as a nega-
tive control. The result is an average of 13 independent
experiments. ***p < 0.001; ‘‘ns’’ indicates no significant
difference versus 4F2hc.
(E) Typical ClC-2 currents in Xenopus oocytes expressed
by itself (left) or coexpressed with HepaCAM2 (right).
HepaCAM2 positive protein expression was assessed by
Western blot (data not shown).
(F) Currentsmeasured inXenopus oocytes at + 60mV after
the expression of ClC-2 alone (3 ng), ClC-2 (3 ng) + Glial-
CAM (5 ng), or ClC-2 (3 ng) + GlialCAM (5 ng) + wild-type
MLC1 (3 ng) or containing the MLC-causing mutations
P92S and S246R (3 ng). The result is a representative
experiment of two experiments with at least 5 oocytes
measured for each condition.
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S5F). Hence the interaction between both proteins may depend
on the transmembrane and/or the N-terminal part of GlialCAM.
Deletion of the N-terminal part of GlialCAM, while keeping the
cleavable signal peptide, resulted in a lack of surface expression
(data not shown), precluding proper biochemical studies.
Impact of MLC-Related Mutations Identified in
GLIALCAM on ClC-2
Several GLIALCAM mutations found in patients with MLC trun-
cate the protein before the transmembrane domain or result in
amino-acid changes in the N-terminal, extracellular part of Glial-
CAM (Lo´pez-Herna´ndez et al., 2011a). We studied four of these
missense mutations located within the IgV domain (Figure 1A).
All GlialCAM proteins containing MLC-causing missense muta-
tions retained their physical interaction with ClC-2 (Figures 7A
and S6A) and increased ClC-2 activity similar to wild-type
GlialCAM in Xenopus oocytes (Figures 7B and S6B) and in trans-
fected cells (data not shown). In contrast, all of them abolished956 Neuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc.the targeting of ClC-2 to cell junctions in HeLa
or HEK293 cells (Figures 7C and 7D).
We also analyzed the effect of the MLC-
causing mutations in GlialCAM on the localiza-
tion of ClC-2 in primary cultures of rat astrocytesthrough adenoviral-mediated transduction (Figure 8). Coexpres-
sion of ClC-2 with GlialCAM mutant variants resulted in intracel-
lular and cell membrane staining of ClC-2 (Figures 8B–8E), but
not the typical wild-type GlialCAM induced localization in cell
junctions (Figure 8A).
DISCUSSION
In this work, we have identified GlialCAM as an interaction
partner of the ClC-2 chloride channel. As ClC-2 is functional in
the absence of GlialCAM, albeit displays different biophysical
properties, and since GlialCAM shows a much more restricted
expression pattern than ClC-2 (Thiemann et al., 1992), it is clear
that GlialCAM is not an obligate b-subunit of ClC-2, but an auxil-
iary subunit that associates with ClC-2 only in some cell types.
MLC1 wild-type or containing MLC-causing mutations, by
contrast, does not modify ClC-2 currents neither in the presence
nor in the absence of GlialCAM, and biochemical studies
indicate that ClC-2 and MLC1 do not interact directly (Duarri
Figure 6. Electrophysiological Characterization of
the GlialCAM/ClC-2 Complex
(A) Dependence on the extracellular osmolarity of ClC-2,
ClC-2 + GlialCAM, or DNClC-2 currents. Gray bars
indicate application of the hypotonic solution. Insets
show typical responses of the same oocytes to a pulse
to 140 mV before swelling.
(B) Reversal potential ofDNClC-2 (n = 5 ± SEM) andClC-2/
GlialCAM (n = 5 ± SEM) currents under different anionic
conditions.
(C) pH dependence of ClC-2 and DNClC-2, each without
and with GlialCAM. Currents were normalized to the value
at pH 7.3. Arrow points to the pH value with the largest
difference between the groups that express or not
GlialCAM.
See also Figure S5.
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A Subunit of ClC-2 Defective in a Leukodystrophyet al., 2011). Furthermore, MLC1 expression and localization is
unaltered in Clcn2/ mice. These data suggest that GlialCAM/
MLC1 and GlialCAM/ClC-2 may form distinct complexes.
Recently, the lack of MLC1 has been correlated with a variable
impairment in cell volume regulation that may be mediated by
the volume regulated anion channel (VRAC) (Ridder et al.,
2011). However, VRAC is distinct from ClC-2 as evident from
very different biophysical characteristics (Jordt and Jentsch,
1997). Furthermore, the mechanism of modulation of VRAC by
MLC1 is unclear. As MLC1 and ClC-2 share GlialCAM as a
subunit, we cannot exclude that MLC1 could regulate ClC-2
function in an indirect/unknown manner. Therefore, an inter-
esting hypothesis that should be tested in the next future is
whether ClC-2 function is altered in cells lacking MLC1.
GlialCAM by itself localizes to cell-cell junctions (Lo´pez-
Herna´ndez et al., 2011b), probably being retained there by
homophilic or heterophilic interactions with membrane proteins
of the apposing cell. In other GlialCAM homolog proteins such
as the members of the SLAM family (Engel et al., 2003), localiza-
tion at the immunological synapse of SLAM proteins is achieved
by trans-homophilic interactions between the IgV domains of
opposite molecules. Furthermore, GlialCAM is also able to
localize ClC-2 and MLC1 (Lo´pez-Herna´ndez et al., 2011b) to
cell-cell junctions in heterologous expression systems and in
primary cultures of astrocytes. The role of GlialCAM as a ClC-2
subunit appears to be specific within its protein family, as its
closest homolog, HepaCAM2, did not interact with ClC-2.
GlialCAM carrying MLC-related mutations (Lo´pez-Herna´ndez
et al., 2011a) fails to arrive at cell-cell junctions (Lo´pez-Herna´n-
dez et al., 2011b). As a consequence, also their associated
subunits, MLC1 and ClC-2, are not properly targeted to cell-
cell junctions. Thus, GlialCAM function may be needed to cluster
ClC-2 and MLC1 in particular to astrocyte-astrocyte junctions at
astrocytic endfeet. Here, the ClC-2 chloride channel may be
needed to support a transcellular chloride flux or to compensateNeuron 73,large electrochemical ion gradients that may
occur at these junctions during ion-driven
changes in osmolarity. However, the chloride
flux mediated by ClC-2/GlialCAM in cell junc-
tionsmost likely fulfills a different role compared
to the one mediated by gap junctions as theseproteins do not colocalize completely. Our experiments also
exclude that GlialCAM activates astrocyte gap junctions, since
their blockade did not influence currents induced by GlialCAM
overexpression, and GlialCAM overexpression had no influence
on connexin 43 protein levels or its subcellular localization.
Recent reports indicated that the ClC-2 channel in neurons
constitutes a part of the background conductance regulating
input resistance and providing an efflux pathway for chloride
(Fo¨ldy et al., 2010; Rinke et al., 2010), which may be a safeguard
mechanism to prevent chloride accumulation in active
GABAergic synapses. In contrast, the role of ClC-2 in glial cells
is unknown. Recordings from mouse slices demonstrated that
ClC-2-mediated current was reduced in reactive astrocytes
within a lesion (Makara et al., 2003). Strong evidence in favor
of an important physiological role of ClC-2 in glial cells is
provided by the phenotype of Clcn2/ mice, which display an
MLC-like vacuolization in the brain (Blanz et al., 2007). Vacuoliza-
tion in the brain has been also observed in mice disrupted for the
potassium channel Kir4.1 (Neusch et al., 2001) or double-disrup-
ted for connexins 32 and 47 (Menichella et al., 2006). These
proteins are thought to be crucial for potassium siphoning by
glial cells, a process that is needed to avoid neuronal depolariza-
tion by extracellular K+ during repetitive action potential firing
(Rash, 2010). In agreement with this role in ion siphoning, in
Kir4.1 knockout mice there was no vacuolation in the optic nerve
after blocking action potential generation with tetrodotoxin
(Neusch et al., 2001). It was neither observed in the Clcn2/
mice possibly because they are blind due to retinal degeneration
(Blanz et al., 2007). Hence degeneration in both mouse models
depend on nerve activity, in accord with the siphoning process
that is required after neuronal repolarization. It has been sug-
gested that ClC-2may play a role in charge compensation during
potassium influx or efflux in glial cells (Blanz et al., 2007).
ClC-2-mediated currents were increased upon GlialCAM
expression and showed less inward rectification. However,951–961, March 8, 2012 ª2012 Elsevier Inc. 957
Figure 7. Biochemical and Functional Conse-
quences of GLIALCAM Mutations on ClC-2
(A) Interaction between ClC-2 and GlialCAM or GlialCAM
containing MLC-related mutations revealed by split-TEV
interaction assays (n = 5).
(B) Average instantaneous currents at +60 mV from ClC-2
expressing oocytes coinjected with saturating concen-
trations of GlialCAM or the indicated GlialCAM variants.
The result is an average of n = 5 in each experiment from
three independent experiments.
(C) Immunofluorescence of HeLa cells expressing ClC-2
plus wild-type GlialCAM or GlialCAM containing the MLC-
related mutations R92Q, R98C, R92W, and G89D. Scale
bar: 10 mm. Expression at contact sites and non-contact
surface membrane was determined by the analysis of the
intensity profile along the dashed line.
(D) Relative fluorescence intensity at cell contacts. Inten-
sity profile analysis revealed that ClC-2 alone had a ratio R
of fluorescence Fcontact/Fsurface (see Experimental Proce-
dures) of 0.7 ± 0.03 (n = 58), ClC-2 + GlialCAM a value of
1.8 ± 0.14 (n = 55), and the GlialCAM variants studied (with
at least 24 pair of cells analyzed) had R values less than 1
(see Experimental Procedures), indicating that the variants
containing MLC-relatedmutations were not able to cluster
ClC-2 to cell junctions. *p < 0.05, **p < 0.01 versus wild-
typeGlialCAMplus ClC-2. Similar results were observed in
HEK cells (not shown).
See also Figure S6.
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A Subunit of ClC-2 Defective in a LeukodystrophyClC-2 activity recorded in cultured astrocytes (Ferroni et al.,
1997) or in astrocytes in brain slices (Makara et al., 2003) resem-
bles that of ClC-2 alone. This may be due to different recording
conditions, or, alternatively, it may be that GlialCAM interacts
with ClC-2 only under special circumstances, such as those
occurring during high neuronal activity.
A polarized distribution of the Kir4.1 channel in astrocyte
membranes in contact with endothelial cells, mediated by
interaction with proteins of the DGC (dystrophin-glycoprotein
complex) (Nagelhus et al., 2004), is required for potassium
siphoning. In an analogous way, the polarized localization
of ClC-2 mediated by GlialCAM in astrocyte-astrocyte or
oligodendrocyte-astrocyte contacts may be also needed to
support a directional flux of potassium from neurons to
blood vessels. As a cell-adhesion molecule, GlialCAM could
influence the expression of other molecules expressed in cell
junctions such as connexins. Similar to DGC proteins, the
localization in cell-cell contacts of GlialCAM itself and of asso-
ciated molecules may be achieved by transmediated interac-
tions or by interactions with intracellular scaffolds in each
cell. It seems possible that GlialCAM may organize a more
extensive cluster of proteins at the astrocytic junctions in the
endfeet.
We propose that the lack of the stimulatory effect of GlialCAM
on ClC-2 currents, or a mislocalization of this Cl channel, or958 Neuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc.both, will impair glial chloride transport. This
may impair not only chloride homeostasis, but
also potassium siphoning and cell volume regu-
lation that is particularly important during
neuronal activity. This in turn may entail accu-mulation of osmotically driven water, lead to the vacuolization
observed in MLC patients with mutations in GLIALCAM or in
Clcn2/ mice. Vacuolization observed in MLC patients with
GLIALCAM mutations could also be due to defects in GlialCAM
by itself, or to a mislocalization of MLC1, an established causal
player inMLC. Additionally, the adhesive properties of GlialCAM,
and their importance for the anatomy of the brain and the path-
ogenesis of MLC remain to be studied.
The fact that so far no disease-causing CLCN2 mutation has
been found in patients with MLC (Blanz et al., 2007; Scheper
et al., 2010) might be explained by the presence of additional
symptoms (e.g., blindness, male infertility, as expected from
the phenotype of Clcn2/ mice [Bo¨sl et al., 2001]) that could
result in improper disease classification. The male infertility
could also lead to an underrepresentation of CLCN2 mutations
in the human population. Thus, proof of the involvement of
ClC-2 in MLC disease will require, for example, immunolocaliza-
tion studies in brain biopsies of MLC patients with GLIALCAM
mutations.
In summary, the discovery of GlialCAM as the first auxiliary
subunit of ClC-2 increases the complexity of regulation of the
CLC chloride transporter/channel family for which so far only
two b-subunits have been described (Este´vez et al., 2001; Lange
et al., 2006). Our work provides new clues to uncover the phys-
iological role of the ClC-2 channel in glial cells, and suggests that
Figure 8. ClC-2 and GlialCAM Subcellular Localization Changes
Caused by GLIALCAM Mutations in Primary Cultures of Astrocytes
(A–E) Astrocytes were cotransduced with adenoviruses expressing ClC-2
together with wild-type GlialCAM (A) or containing the MLC-related mutations
R92Q (B), R98C (C), R92W (D), and G89D (E). Cells were fixed, permeabilized,
and then immunofluorescence was performed with a rabbit polyclonal anti-
body against ClC-2 (green) and a monoclonal antibody detecting GlialCAM
protein (red). Nuclei were stained with DAPI (blue). Colocalization between the
green and the red channel is shown in yellow. Images correspond to repre-
sentative cells from three independent experiments. Scale bar: 20 mm.
Neuron
A Subunit of ClC-2 Defective in a Leukodystrophythe ClC-2 channel may be involved in the physiopathology of
MLC disease.
EXPERIMENTAL PROCEDURES
Biochemistry
Proteomic analysis: for solubilization, membrane vesicles (1 mg) were resus-
pended in ComplexioLyte buffer 47a (at 0.8 mg protein/ml, LOGOPHARM
GmbH, Germany; with protease inhibitors), incubated for 30 min at 4C and
cleared by ultracentrifugation (10 min at 150,000 3 g). 0.8 ml solubilizates
were incubated for 2 hr at 4C with 10 mg of immobilized anti-rabbit GlialCAM(Lo´pez-Herna´ndez et al., 2011a), anti-mouse GlialCAM (Vitro, Spain) and
control IgG (Upstate, USA), respectively. After brief washing (2 3 5 min) with
ComplexioLyte 47a, bound proteins were eluted with Laemmli buffer (DTT
added after elution). Eluates were shortly run on SDS-PAGE gels and silver-
stained prior to tryptic digestion for MS analysis. LC-MS/MS analysis was per-
formed as described (Lo´pez-Herna´ndez et al., 2011a). Immunoprecipitation
and western blot studies of HeLa cells transiently transfected or solubilized
rat brain to confirm protein-protein interactions with ClC-2 and GlialCAM anti-
bodies was performed as described (Lo´pez-Herna´ndez et al., 2011a). Relative
MS sequence coverage of ClC-2 protein (Figure S1) was calculated as SC =Ni/
(Ni + Nan), where Ni is the number of amino acid residues of the identified
peptides (with Mascot score R 20) and Nan is the number of MS-accessible
but not identified amino acids (peptides with mass of 740–3,000 u) of the
respective Swiss-Prot sequence.
Molecular Biology
Rat ClC-2 and the N-terminal deletion (D16–61) mutant DN (Gru¨nder et al.,
1992) constructs for expression in oocytes were in the pTLN vector (Lorenz
et al., 1996). For localization studies in HEK293 or HeLa cells, rClC-2 and
DN were C-terminally fused to GFP or to flag. DmClC-2 and ClC-2 with an
HA extracellular tag was provided by LP Cid (Centro de Estudios Cientı´ficos,
Chile). GlialCAM-DC was constructed eliminating residues from 289 until the
stop codon.
Voltage-Clamp Experiments
Xenopus oocytes were injected and maintained as described (Este´vez et al.,
2003). For ClC-2, 5 ng cRNA and for DN 0.25 ng cRNA/oocyte were injected.
When coexpressing, 1.25 ng cRNA of GlialCAM were coinjected with ClC-2.
Oocytes were perfused with (in mM): 100 NaCl, 5 MgSO4, and 10 HEPES/
NaOH (pH 7.3). To estimate the specific ClC-2-mediated chloride currents,
iodide (100 mM NaI replacing the NaCl), which blocks ClC-2-mediated
outward currents (Gru¨nder et al., 1992; Thiemann et al., 1992), was applied
in every experiment. Oocyteswhich did not exhibit a significant block were dis-
carded. For selectivity experiments (Figure 6B), 100 mM Cl was exchanged
by 100 mM of the tested anion. For pH experiments, 10 mM buffer was used
(pH 10–9: CAPS [N-cyclohexyl-3-aminopropanesulfonic acid]; pH 8–7:
HEPES; pH 6–5: MES; and pH 4: Glutamic acid). Hypotonicity effects were
studied as described (Gru¨nder et al., 1992). For ClC-2, an initial 1 s voltage
pulse at +60 mV was applied, followed by 5 s voltage steps from 140 mV
to +60 mV in 20 mV increments and a tail pulse of 1 s to 60 mV. To quantify
expression levels, the initial tail current (at +60 mV) after the 140 mV test
pulse was estimated by back extrapolation of a single exponential fit to the de-
caying tail current. To estimate the number of constitutively active channels,
instantaneous currents were measured during a short test pulse to +60 mV
without prior activation by hyperpolarization.
Patch-Clamp Experiments
Fluorescent HEK293 cells, expressing CLC-2-GFP or DN-GFP with or without
GlialCAM, were measured with an extracellular solution containing (in mM):
140 NaCl, 2 MgSO4, 2 CaCl2, and 10 HEPES/NaOH (pH 7.3) using standard
patch-clamp technique. Intracellular solution was (in mM) 130 NaCl,
2MgSO4, 2 EGTA, and 10 HEPES/NaOH (pH 7.3). Only cells for which currents
were reversibly blocked by iodide were used for analysis. Patch-clamp of
astrocytes was performed as described (Ferroni et al., 1997).
Surface Expression by Chemiluminescence
Surface expression in transfected mammalian cells or astrocytes was per-
formed similarly as previously described (Duarri et al., 2008; Teijido et al.,
2004). Briefly, 48 hr after transfection, cells were cleaned with PBS and fixed
with 3% paraformaldehyde. After PBS washing, cells were blocked with 1%
BSA in PBS for 30 min, and incubated with 1 ml of 3F10 anti-HA antibody at
0.2 mg/ml in blocking solution for 1 hr at RT. Cells were washed six times
with blocking solution, and incubated for 20 min with 1 ml of a 1:1,000 dilution
horseradish peroxidase-coupled secondary antibody (donkey anti-rat IgG,
Jackson, Suffolk, UK) in blocking solution. Cells were washed four times
with blocking solution and eight times with PBS. LuminescencewasmeasuredNeuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc. 959
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A Subunit of ClC-2 Defective in a Leukodystrophyof one dish at a time with 500 ml of Power Signal ELISA solution (Pierce) in
a Turner TD-20/20 luminometer (Turner Biosystems, Madison, WI, USA).
Immunological Procedures
Two immune sera against ClC-2 were generated against overlapping
sequences of the C terminus. In the first antibody (C1 Ab), the peptide used
for immunization was (C)HGLPREGTPSDSDDKSQ. The native protein
sequence contains a cysteine residue instead of the highlighted serine in order
to avoid coupling this residue to the carrier protein. In the second antibody (C2
Ab), the peptide used for immunization was (C)RSRHGLPREGTPSDSDD. (C) is
the cysteine that was used for coupling. Affinity purification of the antibodies
was used as described (Lo´pez-Herna´ndez et al., 2011a). Mostly, the C1 anti-
body was used in western blot studies, and the C2 antibodywas used in immu-
noprecipitation, immunocytochemistry, and EM immunogold. Both antibodies
gave no staining in the Clcn2/ mice.
Primary Culture and Adenoviral Transduction
Rat primary quiescent astrocyte cultures were prepared as described previ-
ously (Duarri et al., 2008). Dibutyryl-cAMP differentiated rat astrocytes were
obtained as described (Ferroni et al., 1997). Adenoviruses expressing three
copies of the flag epitope fused to human GlialCAM, either wild-type or con-
taining mutations have been described (Lo´pez-Herna´ndez et al., 2011a).
Adenoviruses expressing GlialCAM fused to EmGFP or ClC-2 fused to three
copies of the Flag epitope or containing an extracellular HA epitope were con-
structed in a similar manner. Transduction of astrocytes was performed as
already described (Lo´pez-Herna´ndez et al., 2011a).
Immunofluorescence and Electron Microscopic Studies
Tissue immunohistochemistry and immunofluorescence were performed as
previously described (Blanz et al., 2007; Teijido et al., 2004). For electron
microscopic studies, human cerebellum samples were processed as previ-
ously described (Lo´pez-Herna´ndez et al., 2011a).
Quantification of Localization in Cell Contacts
Image J (http://rsbweb.nih.gov/ij/) was used to quantify fluorescence at cell
contacts and in the plasma membrane at cell contact free sites by performing
intensity profile experiments. We defined a ratio (R) considering the fluores-
cence signal at the plasma membrane of two cells (cell 1 and cell 2) and the
signal in junctions. [R = Fjunction/(Fmembrane1+Fmembrane2)]. Thus, if the R value
is > 1, the signal will be concentrated at junctions.
Split-TEV Method
Split-TEV (Tobacco etch virus protease) assays were performed as described
(Lo´pez-Herna´ndez et al., 2011b). We used a mutant form of the TEV protease
(S219V) which prevents its self-digestion but does not affect its catalytic effi-
ciency. The oligopeptide substrate used as the TEV protease-recognition
site was ENLYFQS, and the chimeric transcription factor used was GV (ob-
tained from the pM3-VP16 vector) (Clontech, Nucliber, Madrid, Spain), which
contains the yeast Gal4DNA binding domain and the herpes simples VP16
transactivaction domain. After TEV protease cleavage, GV translocates into
the nucleus and induces the reporter Gaussia Luciferase gene expression
(pNEBr-X1Gluc) (New England BioLabs, IZASA, Barcelona, Spain), which is
secreted into the cell culture medium.
TEV protease was divided in two fragments: the TEV-N (residues 1–118) and
the TEV-C (residues 119–242). We fused the TEV-N fragment, the TEV
protease recognition site and the chimeric transcription factor GV to the
C-terminal of ClC-2, the mutant DNClC-2, or DmClC-2 in a pCDNA3 vector
containing a CMV promoter. In addition, we fused the TEV-C fragment to the
C-terminal of ClC-2, ClC-5, DNClC-2, GlialCAM wild-type, HepaCAM2, Glial-
CAMDC, GlialCAM containing the mutations R92Q, R98C, R92W, and
G89D, and the adenosine 2A receptor. The fusion of the TEV-C fragment to
4F2hc was done N-terminal. All the proteins with the TEV-C fragments were
cloned in a pCDNA6.2/V5-pL Dest, containing the herpes simplex virus thymi-
dine kinase (HSV-TK) promoter, to provide low to moderate levels of
expression.
All the expression plasmids were constructed by PCR using a polymerase
with proofreading (KOD Hot Start polymerase, Calbiochem, Darnstadt,960 Neuron 73, 951–961, March 8, 2012 ª2012 Elsevier Inc.Germany), adding the attB1, attB2, attB5R, or attB5 recombination sites
compatible with the Multisite Gateway System (Invitrogen, Carlsbad, CA,
USA). All protocols were performed according to the manufacturer’s instruc-
tions (Invitrogen).
HeLa cells were transiently transfected with the corresponding cDNA
constructs. The total DNA transfected was 2 mg, with the following ratios:
0.75 mg of each protein containing the TEV-N and the TEV-C fragments,
0.3 mg of the reporter gene pNEBr-X1GLuc, and 0.2 mg of the pCMV-bGal
vector, which was used to monitor the transfection efficiency. After 48 hr,
20 ml were removed from the supernatant of the cells and Gaussia luciferase
activity was measured in a TD-20/20 luminometer (Turner BioSystems, Madi-
son, USA), after the addition of 20 mMof native colenterazine. To normalize the
data, cells were solubilized and 30 ml of the cell lysates were used to measure
the b-Galactosidase enzyme activity using the Luminiscent b-Galactosidase
Detection Kit II (Clontech) in the same luminometer.
Statistical Analyses
For determination of the statistical significance between groups, either the
Student’s t test or the Bonferroni’s comparison test were used. p values are
annotated in each figure. Values depicted are means ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at doi:10.1016/j.neuron.2011.12.039.
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